Is antiviral prophylaxis necessary to prevent hepatitis b virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4480-

  Kusumoto, Shigeru ^a   Tanaka, Yasuhito ^a   Mizokami, Masashi ^b   Ueda, Ryuzo ^c  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RITUXIMAB; ANTINEOPLASTIC AGENT; GUANINE; MONOCLONAL ANTIBODY; DRUG DERIVATIVE;

ARTICLE; CHEMOTHERAPY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; LIMIT OF DETECTION; LIVER FAILURE; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; VIRUS LOAD; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FEMALE; LYMPHOMA; MALE; VIROLOGY; VIRUS ACTIVATION; DRUG EFFECT; NOTE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LYMPHOMA; MALE; VIRUS ACTIVATION;

EID: 84894292002     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.1278     Document Type: Article

References (6)

1. Huang YH, Hsiao LY, Hong YC, et al: Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31:2765-2772, 2013
2. US National Institutes of Health: ClinicalTrials.gov archive. http://clinicaltrials.gov/archive/NCT00926757/2013-05-28/changes
3. Roche Diagnostics: Package insert, COBAS AMPLICOR HBV MONITOR Test. Revision 6.0, 2009
4. Oketani M, Ido A, Uto H, et al: Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42:627-636, 2012
5. European Association for the Study of the Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185, 2012
6. Kusumoto S, Tanaka Y, Suzuki R, et al: Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reactivation in patients with B-cell non-Hodgkin lymphoma following rituximab containing chemotherapy: Results of interim analysis. Blood 120, 2012 (abstr 2641)